Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEGALiT: Genomics-Guided Treatment in Advanced Cancer
NCT04185831Phase 2Active, not recruiting
- Sponsor
- Akademiska sjukhuset
- Start
- Oct 2020
- Primary completion
- Jan 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of cobimetinib, everolimus, atezolizumab and niraparib in solid tumor (4 cohorts), sponsored by Akademiska sjukhuset. Primary endpoints: Objective Response Rate at 24 months and Tumor Control Rate at 24 months. Started Oct 2020; status: active, not recruiting.
02
Drugs
cobimetinibeverolimusatezolizumabniraparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04185831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04185831.